Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

(UPDATED) The study, when coupled with FIDELIO-DKD, now opens up finerenone to diabetic patients with a wide range of CKD.

Related Keywords

Austria ,Athens ,Attikír ,Greece ,Ann Arbor ,Michigan ,United States ,Vienna ,Wien ,Gerasimos Filippatos ,Kurt Huber ,Bertram Pitt ,European Society Of Cardiology Congress ,Bayer Ag ,Astrazeneca ,Md Sigmund Freud University Medical School ,Md Attikon University Hospital ,Md University Of Michigan School Medicine ,Michigan School ,Hot Line ,European Society ,Cardiology Congress ,New England Journal ,Attikon University Hospital ,Sigmund Freud University Medical School ,